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Primary ciliaSonic hedgehog (Shh) signaling is essential for proliferation of cerebellar granule cell progenitors (cGCPs) and its
aberrant activation causes a cerebellar cancer medulloblastoma. Pituitary adenylate cyclase activating polypep-
tide (PACAP) inhibits Shh-driven proliferation of cGCPs and acts as tumor suppressor in murine medulloblasto-
ma. We show that PACAP blocks canonical Shh signaling by a mechanism that involves activation of protein
kinase A (PKA) and inhibition of the translocation of the Shh-dependent transcription factor Gli2 into the primary
cilium. PKA is shown toplay anessential role in inhibiting gene transcription in the absence of Shh, but global PKA
activity levels are found to be a poor predictor of the degree of Shh pathway activation.We propose that the core
Shh pathway regulates a small compartmentalized pool of PKA in the vicinity of primary cilia. GPCRs that affect
global PKA activity levels, such as the PACAP receptor, cooperatewith the canonical Shh signal to regulate Gli pro-
tein phosphorylation by PKA. This interaction serves to ﬁne-tune the transcriptional and physiological function of
the Shh pathway.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. 1. Introduction
The Sonic hedgehog (Shh) signaling pathway, which is involved in
embryonic and postnatal development in humans andmany other spe-
cies, is also abnormally activated in several types of cancer [1]. The out-
put of the pathway in vertebrates is mediated by a family of Gli
transcription factors, but the processes that lead to Gli activation fol-
lowing the binding of Shh to its receptor Patched (Ptch) have not
been fully elucidated [2]. It is known that Shh causes activation of
a 7-transmembrane domain (7-TM) protein Smoothened (Smo),
which under basal conditions is suppressed by Ptch. De-repression
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. Open access under CC BY-NC-ND licetwo major Gli inhibitors— Protein Kinase A (PKA) and Suppressor of
Fused (SuFu). However, the steps of the pathway that transduce the
signal from Smo to PKA and SuFu remain poorly understood.
The regulation of Shh signaling by PKA has been extensively studied.
In the absence of signal, Gli proteins are directly phosphorylated by PKA
[3], which results in their conversion into transcriptional repressors, and
ultimately leads to abrogation of Shh target gene expression [4]. Con-
versely, inhibition of PKA activity results in the formation of transcrip-
tional activator forms of Gli proteins, which leads to activation of Shh
target genes [5,6]. These data suggest that PKA is required to maintain
lowbaseline levels of Shh-dependent transcripts, but until recently little
was known about the possible ways inwhich Shhmight antagonize this
inhibitory function of PKA. It has been hypothesized that Smo acts as a
G-protein coupled receptor (GPCR) and inhibits PKA by inducing the
Gi-family of heterotrimeric GTPases [7–9], but this view has been con-
troversial [10,11]. The Smo–Gi link has later been suggested to represent
a non-canonical branch of the pathway [12]. On the other hand, recent
work shows that Smo regulates the subcellular localization of another
GPCR, Gpr161, which turns out to be crucial for the canonical PKA-
mediated inhibition of Gli protein function [13]. Regardless of the
mode of regulation of the PKA–Gli interaction by Smo, there remains a
major question of how Hh signaling can remain robust to changes in
PKA activity caused by GPCRs utilizing Gαs, which positively couple to
the adenylate cyclase (AC)/PKA pathway. Conversely, it is not clear if
in some cases these GPCRs might be used to adjust Shh transcriptional
response based on environmental cues.
Much recent interest in Shh signaling stems from the fact that this
pathway is involved in a broad range of human cancers [14]. Innse. 
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common pediatric brain tumor, are thought to be driven by germline
and acquired genetic mutations in Shh pathway components [15,16]. Ac-
cordingly, mice harboring activatingmutations of Smo or lacking a single
copy of Ptch develop MB-like tumors [15]. These Shh-dependent MBs
arise from a class of precursor cells known as cerebellar granule cell pro-
genitors (cGCPs) [17], whose rapid postnatal proliferation is critically de-
pendent on Shh secreted from the Purkinje cells of the cerebellum [15].
Various signals, including the extracellular matrix [18] and secreted pep-
tides [19–21], cooperatewith Shh to regulate the proliferation and differ-
entiation of cGCPs. Failure of these mechanisms may contribute to
uncontrolled proliferation of cGCPs, leading to the generation of MB
tumors.
Our particular interest is in the role of pituitary adenylate cyclase-
activating polypeptide (PACAP) in cGCP proliferation and MB tumori-
genesis. PACAP is a short secreted polypeptide with ubiquitous expres-
sion and pleiotropic functions [22]. Both PACAP and its receptors are
expressed in the cerebellum at the peak of cGCP proliferation [23–25]
and PACAP can inhibit Shh-driven cGCP proliferation in vitro [26]. Im-
portantly, we found that incidence of MB in mice lacking a single copy
of Ptch is increased three fold by an additional heterozygous mutation
in the gene encoding PACAP [27]. We hypothesized that the tumor sup-
pressor role of PACAP in MB was due to a direct inhibitory effect of
PACAP on Shh signaling in cGCPs. On the other hand, a recent study
linked the antiproliferative effect of PACAP with the expression of the
transcription factor Lot1 [28], suggesting that the effects of PACAP on
cGCP proliferation are independent of Shh signaling. Further work was
therefore necessary to resolve the controversy surrounding the mecha-
nism of the antiproliferative action of PACAP in cerebellar development.
In the presentwork, we show that the inhibitory effects of PACAP on
cGCP proliferation are mostly due to the direct effect of PACAP on Shh
signaling. We further demonstrate that PACAP acts by inducing the ac-
tivity of PKA, which leads to changes in subcellular localization of the
transcription factor Gli2. Finally, we use the PACAP/Shh interaction to
show that elevated total cellular PKA activity can coexist with moder-
ately high levels of Shh signaling, which runs counter to the current
views of Shh pathway regulation by PKA.We explain this apparent par-
adox by proposing a newmodel involving PKA activity compartmental-
ization. This model both explains the apparent robustness of the Shh
signal in the face of PKA activity ﬂuctuations, and shows how various
GPCRs can serve to ﬁne-tune the response of cells to the Shh ligand.
2. Material and methods
2.1. Culture of primary cGCPs
Primary cGCPswere isolated and cultured as detailed in Hatten et al.
[29] with somemodiﬁcations. Brieﬂy, postnatal day 3mouse pupswere
anesthetizedwith pentobarbital and sacriﬁced by decapitation. Cerebel-
la were dissected in calcium and magnesium-free HBSS and meninges
peeled off using ﬁne tweezers. Cerebella were moved into a trypsin/
DNAse solution and minced. Following a 5-minute incubation at room
temperature, the cell suspension was pelleted by centrifugation and
the supernatant was replaced with cold DNAse solution. The cells
were gently dissociated by trituration with ﬁre polished Pasteur
pipettes and pelleted by centrifugation. The cells were resuspended in
DNAse solution and diluted with ice-cold HBSS. Granule cells were
separated from cell debris and other cerebellar cells by centrifuga-
tion on a 35%/60% Percoll gradient, and the interface between the
35% and the 60% Percoll layers was collected. The cells were pelleted
and then resuspended in culture media containing Neurobasal,
penicillin/streptomycin/glutamine (Invitrogen, 1×), 1 mM sodium
pyruvate, 0.04 μg/mL triiodothyronine, 0.1 mg/mL BSA, 0.04 μg/mL
sodium selenite, 60 μg/mL N-acetylcysteine, 0.06 μg/mL progester-
one, 5 μg/mL insulin, 100 μg/mL apo-transferrin, and 16 μg/mL pu-
trescine. Purity of the cultures (90–95%) was ascertained by phase-contrast microscopy, where cGCPs present a very characteristic mor-
phology with small cytoplasm-poor cell bodies and multiple projec-
tions. In experiments using SDF-1 themedia was supplemented with
20 mM KCl (ﬁnal KCl concentration 25 mM), which was required for
SDF-1 to have an effect on Shh signaling. Additional KCl did not im-
pact the effects of Shh-N and PACAP. The cells were plated at
2.5 × 105 cells/cm2 on poly-D-lysine (0.01%)-coated 4-well culture
dishes (Nunc), and treated as described. The treatment time was
2 h for western blot analysis and 6 h for RT-PCR, unless otherwise
indicated.
2.2. [3H]-thymidine incorporation
cGCPs were isolated as above and plated at 3 × 105 cells/cm2 on
poly-D-lysine coated 96-well culture dishes (Nunc). The cells were
grown in the presence or absence of drugs for 24 h and [3H]-thymidine
(1 μCi/well) was added during the last 6 h of incubation. DNAwas pre-
cipitated for 30 min using 5% trichloroacetic acid, washed with PBS,
resolubilized using 0.5 M NaOH/0.5% SDS, transferred into scintillation
liquid (Econo-Safe, RPI) and incorporated radioactivity was counted
on a liquid scintillation counter (Beckman).
2.3. RNA extraction and real-time quantitative RT-PCR
RNA was extracted from CB GCP cultures with the TRIzol reagent
(Invitrogen) following the manufacturer's instructions. In order to
aid RNA pellet visualization glycogen (1 mg)was added to each sample.
cDNA was generated using the iScript cDNA synthesis kit (Bio-Rad)
and quantitative PCR was performed using the iQ SYBR green supermix
(Bio-Rad). The results were analyzed using the standard curve method
with GAPDH used as the housekeeping gene. Primers used for qPCR
were as follows: GAPDH: forward — ggccttccgtgttcctac, reverse —
tgtcatcatacttggcaggtt, Gli1: forward — atctctctttcctcctcctcc, reverse —
cgaggctggcatcagaa, mycN: forward — ggatgatctgcaagaacccag,
reverse— gtcatcttcgtccgggtagaa, ccnd1: forward— tgcggaaaatcgtggc,
reverse — aggaagcggtccaggtagttc, Ptch1: forward — agagcgaagtttc
agagactc, reverse— aaatatgaggagacccacaac. Each set of primers was vali-
dated by cloning and sequencing of the PCR product.
2.4. Microarray analysis
cGCPs were cultured as detailed above and treated for 6 h with or
without Shh-N (1 μg/mL), PACAP (10 nM), or both. RNA extracted
fromeach treatmentwas pooled fromat least 6 samples per experiment
and from 3 to 4 independent experiments. Three samples for each treat-
ment group were generated in this way. Each RNA sample was
processed for microarray hybridization at the UCLA DNA Microarray
Core and the generated cDNA was hybridized to the Affymetrix
GeneChip Mouse Genome 430 2.0 microarray. Results were processed
using the Affymetrix Expression Console using the Plier algorithm for
conversion of raw data into expression values.
2.5. Generation and culture of PAC1-expressing NIH/3T3 ﬂp-in cells
(PAC1 FI)
Stable cell lines expressing low levels of the PAC1 receptorwere gen-
erated using the ﬂp-in system (Life Technologies). Brieﬂy, the PAC1 re-
ceptor (the short/null variant) was cloned from the adult mouse brain
cDNA by means of PCR ampliﬁcation and ligation into the pENTR2B
plasmid. The insert was transferred into the pEF5/FRT/V5-DEST plasmid
by Gateway cloning. NIH/3T3 ﬂp-in cells (Life Technologies) were co-
transfected with the pOG44 and the pEF5/FRT/V5-DEST-PAC1 plasmids,
and stable integrants were selected using hygromycin. The cells were
cultured in media containing high-glucose DMEM, sodium pyruvate,
Gluta-MAX, MEM non-essential amino acids, penicillin/streptomycin,
2224 P. Niewiadomski et al. / Cellular Signalling 25 (2013) 2222–2230and 10% fetal bovine serum (FBS). 18–36 h before the experiment, the
cells were serum-starved in media containing 0.5% FBS.2.6. Protein extraction and western blot analysis
Proteins were extracted from cell cultures with NP-40 lysis buffer
containing protease and phosphatase inhibitors. Total proteinwas quan-
tiﬁed using the detergent resistant Bio-Rad protein assay (Lowry) and
equal protein samples were resolved by SDS-PAGE electrophoresis.
Protein was transferred onto PVDF or nitrocellulose membranes and
equal loading was ascertained by Ponceau S staining. The membranes
were blotted with the following antibodies: anti-phospho-PKA sub-
strates (Cell Signaling #9624), anti phospho-PKC substrates (Cell Signal-
ing #2261) anti-ERK and anti-phospho-ERK, anti-MEK1/2 and anti-
phospho-MEK1/2 (all from Cell Signaling). Chemiluminescent detection
was performed using secondary antibodies coupled to HRP and ECL or
ECL + substrates (GE Healthcare) and Kodak BioMax Light ﬁlm. For ex-
periments on PAC1 FI cells the primary antibodies used were: anti-Gli1
(Cell Signaling #2643), guinea pig anti-Gli2 (kindly provided by Dr.
Rajat Rohatgi), anti-lamin A (abcam), anti-α-tubulin (Sigma). For these
experiments, secondary antibodies were coupled to IRDye ﬂuorophores
and the membranes were imaged on the Li-Cor Odyssey apparatus.2.7. Immunoﬂuorescence
PAC1 FI cells were cultured on round glass coverslips. They were
starved in media containing 0.5% FBS for 24 h, and then treated for
2 h with the indicated drugs. The cells were ﬁxed in 4% paraformalde-
hyde for 10 min, and then permeabilized/blocked in blocking solution
(PBS + 0.1% Triton X-100, 1% normal donkey serum, 1% BSA) for
30 min. Primary and secondary antibodies were diluted in blocking so-
lution. Primary antibody incubation was 1 h at room temperature, and
secondary antibody incubation was 30 min at room temperature. Both
antibody incubations were followed by 3 × 5 min wash in PBS + 0.1%
Triton X-100. The coverslips were mounted on microscope slides
using the ProLong Gold mounting media with DAPI. The cells were im-
aged on the Leica SP5 confocal microscope and stacks of 10 confocal
slices were taken for each image, which were subsequently ﬂattened
by maximum intensity projection. For unsupervised quantiﬁcation of
ciliary tip ﬂuorescence, a custom-made Jython script was used in the
Fiji software suite.2.8. Nuclear-cytoplasmic fractionation
Nuclear-cytoplasmic fractionation was performed as described pre-
viously [30].2.9. Statistical data analysis
Statistical data analysis was performed in Microsoft Excel using spe-
cializedworksheets to calculate p values for Student t-test. Graphswere
plotted using R. Error bars on all charts represent standard deviation of
4–10 measurements of independent samples.2.10. Chemicals
PACAP-38 (referred to as “PACAP” throughout the text), and other
drugs were purchased from Calbiochem, unless otherwise indicated.
Shh-N (mouse, recombinant) was purchased from R&D. Mouse SDF-1α
was purchased from Peprotech. Forskolin was purchased from Sigma.
SAG was purchased from Axxora.3. Results
3.1. PACAP antagonizes Shh-driven proliferation of cGCPs and Hh target
gene expression
We previously reported that PACAP antagonizes Shh-driven BrdU
incorporation into cultured cGCPs [26]. Similarly, we found here that
[3H]-thymidine incorporation into the DNA of cGCPs is increased by
treatment with the Shh N-terminal fragment (Shh-N) (1 μg/mL) and
that this increase is attenuated by treatment with 10 nM PACAP
(Fig. 1A). In order to determine if the effect of PACAP on cGCPs might
result speciﬁcally from the inhibition of Shh pathway rather than from
a direct effect on proliferation, we performed DNA microarray analysis
on mRNA from cGCPs treated for 6 h with Shh-N (1 μg/mL), PACAP
(10 nM), or both. In Shh-N-treated cells PACAP downregulatesmultiple
direct and indirect Shh target genes (Fig. 1C) including Gli1 and Ptch1,
two universal markers of Hh pathway activation, and cyclin D1, a
known Hh effector gene that drives cGCP proliferation. Of all the genes
upregulatedmore than 1.5-fold by treatmentwith Shh-N (98 probesets),
33% (32 probesets) were signiﬁcantly (p b 0.05) downregulated and
none (0%) are signiﬁcantly upregulated by the addition of PACAP
(n = 3 samples for each group). In contrast, of the 112 probesets
upregulated more than 1.5-fold by PACAP treatment, none (0%) were
signiﬁcantly up- or downregulated by the addition of Shh-N (Fig. 1B,
Supplementary Table 1B). This suggests that the antiproliferative effect
of PACAP depends to a large degree on its ability to inhibit Shh signaling
as opposed to a more general induction of genes that arrest prolifera-
tion. PACAP antagonizes the Shh-mediated induction of Gli1 gene ex-
pression in the presence of protein synthesis inhibitor cycloheximide,
suggesting that the effect of PACAP on Shh signaling is direct, and not
mediated through the transcription of additional PACAP target genes
(Fig. 1D).3.2. PACAP regulates the Shh pathway through PKA
To further understand the mechanism of PACAP-mediated inhibi-
tion of Shh signaling, we used phospho-speciﬁc antibodies to test
what signaling pathways were activated in cGCPs in response to
PACAP treatment. PACAP is known to activate the AC/PKA pathway,
the DAG/IP3/protein kinase C (PKC) pathway, the ERK pathway, and
phosphoinositide-3 kinase (PI3K) signaling [22,31,32]. We found that
in cGCPs PACAP does not appear to have an effect on MEK1/2 activity,
but that it stimulates the phosphorylation of substrates of PKA, PKC
and PI3K (Figs. 2A, S1A). Inhibition of PKC and PI3K has no effect on
the ability of PACAP to block Shh-mediated Gli1 production, suggesting
that these two kinases don't participate in the Shh-PACAP interaction in
cGCPs (Fig. 2B). That left PKA as the most plausible mediator of the in-
hibition of Shh signaling by PACAP. Accordingly, the dose-response of
the effect of PACAP on PKA activity closely parallels that of its effect
on Gli1 production (Fig. 1A). To provide further evidence that PKA acti-
vation is involved in the inhibitory effect of PACAP on cGCPs, we tested
other pharmacological activators of the AC/PKA pathway for their abil-
ity to inhibit Gli1 production in cGCPs. Indeed, forskolin, anAC activator,
and N6-benzoyl-cAMP, a direct selective activator of PKA, both mimic
the effect of PACAP on Gli1 gene expression (Fig. 2C).
AC/cAMP signaling, in addition to stimulating PKA, also activates a
class of guanidine nucleotide exchange factors known as cAMP-GEFs.
In fact PACAP was shown to induce cAMP-GEF activity in hippocampal
neurons [33]. In order to rule out the involvement of cAMP-GEFs in
PACAP-mediated inhibition of the Shh pathway, we co-treated cGCPs
with Shh and the cAMP-GEF activator 8-CPT-2-Me-cAMPS. This com-
pound, used at doses known to be sufﬁcient for cAMP-GEF activation,
failed to block Shh-induced Gli1 expression, suggesting that cAMP-
GEF activation by PACAP is not sufﬁcient for its effects on Shh signaling
in cGCPs (Fig. 2D).
Fig. 1. PACAP antagonizes Shh-driven cGCP proliferation and target gene expression. (A) Cell proliferation was measured by [3H]thymidine incorporation in cGCPs cultured for
24 h in deﬁned media supplemented with Shh-N (1 μg/mL), PACAP (10 nM) or both. (B, C) cGCPs were cultured for 6 h in deﬁned media in the presence or absence of Shh-N
(1 μg/mL) and/or PACAP (10 nM). RNA was isolated from the cells and subjected to GeneChip analysis. (B) Left panel shows all probesets upregulated at least 1.5-fold by
Shh-N and right panel shows all probesets upregulated at least 1.5-fold by PACAP. Individual lines represent probesets. Colors were assigned arbitrarily and are related to the
degree of upregulation of gene expression by Shh-N (left) or PACAP (right). (C) Expression of individual known Shh target genes Gli1, Ptch1, and cyclin D1 (Ccnd1) was analyzed
as above. *— p b 0.05 relative to control, a— p b 0.05 relative to Shh alone. (D) cGCPs were cultured for 30 min in the presence or absence of 10 μg/mL cycloheximide (CHX), and
then Shh-N and/or PACAP was added to the culture media for additional 6 h. Gli1 expression was assayed by quantitative RT-PCR.
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Since PACAP appears to blocks Shh signaling through induction of
PKA,we hypothesized that inhibition of PKAwould stimulate Shh target
genes in cGCPs. Such effects have previously been observed in the de-
veloping spinal cord [5,6] and in mouse embryonic ﬁbroblasts [34].
Treatment of cGCPs with the PKA inhibitor H89 (10–30 μM) caused a
dose-dependent increase in Gli1 expression (Fig. 3A) and a correlated
reduction in PKA activity (Fig. 3B). At the highest dose used (30 μM)
H89 induces Gli1 expression to the same extent as Shh-N (1 μg/mL)
and the combination of Shh-N plus H89 does not produce any further
increase in Gli1 mRNA levels over that induced by either drug alone.
Consistent with the hypothesis that PACAP acts on Shh signaling
through PKA induction, PACAP does not abrogate H89-induced in-
crease in Gli1 expression (Fig. 3C). Also, two other PKA inhibitors,PKI and Rp-cAMPS, induce Gli1 production in cGCPs, albeit less effec-
tively than H89 (Fig. 3D). These data provide evidence for the essen-
tial role of PKA in repressing Shh target gene expression in the
absence of signal, but do not explain how this baseline PKA activity
is maintained in the absence of Shh and PACAP.
3.4. SDF-1 signaling through Gαi ampliﬁes Shh-N response to induce Gli1
expression
GPCRs can regulate AC activity in two ways: receptors coupled to
Gαs, such as the PACAP receptor, activate AC, whereas receptors that
bind Gαi block AC and act as inhibitors of PKA activity. Thus, Gαi-coupled
receptor stimulation shouldmimic the effect of pharmacological inhibi-
tion of PKA. cGCPs express CXCR4, a Gαi-coupled 7-TM receptor that
binds SDF-1, a peptide secreted by the pia matter of the cerebellum
Fig. 2. PACAP regulates Gli1 gene expression dose-dependently by induction of PKA. (A) cGCPs were cultured in the presence of indicated doses of peptides and drugs. Gli1 RT-PCR was
performed on RNA isolated after 6 h of treatment.Western blots were performed on protein isolated after 2 h of treatment. The effect of PACAP on Shh-N-induced Gli1 gene expression is
shown in the top panel, and phosphorylation of PKA target proteins under the same conditions is shown in the bottompanel; **— p b 0.01 relative to control, @— p b 0.05 relative to Shh
alone, @@— p b 0.01 relative to Shh alone (B) cGCPswere pretreated for 30 minwith inhibitors of PKC (GF109203X; 5 μM),MAPK1/2 (PD980059; 25 μM), and PI3K (LY294002; 10 μM),
and then treatedwith Shh-N (1 μg/mL), PACAP (10 nM) or both for 6 h in the presence of the inhibitor. Gli1 gene expression was assayed by quantitative RT-PCR; *— p b 0.05, and ***—
p b 0.001 relative to kinase inhibitor alone, @@@— p b 0.001 relative to Shh + kinase inhibitor. (C, D) cGCPswere pretreated for 30 minwith the AC activator forskolin (FSK; 5 μM), spe-
ciﬁc activator of PKAN6-benzoyl-cAMP (Bnz-cAMP; 300 μM), and a Smo antagonist SANT-1 (1 μM) (C) or the cAMP-GEF activator 8-CPT-2-Me-cAMPS (8-CPT; D) and then treated for 6 h
with Shh-N. Gli1 gene expression was measured as in (A). n/s — non-signiﬁcant relative to Shh alone, *** — p b 0.001 relative to Shh alone.
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proliferation of cGCPs in the presence of Shh-N in a pertussis toxin
(PTX)-sensitive manner [21]. We hypothesized that SDF-1 exerts its ef-
fect on cGCP proliferation by enhancing Shh signaling through PKA in-
hibition. Indeed, even though SDF-1 does not have a signiﬁcant effect
on Gli1 expression either in the complete absence of Shh-N or in the
presence of a saturating dose of Shh-N, it nevertheless ampliﬁes the
response to a suboptimal dose (0.03 μg/mL) of Shh-N (Fig. 3E). However,
in contrast to PACAP, wewere unable to show a direct effect of SDF-1 on
PKA activity (Fig. S2). Thismay reﬂect the fact that SDF-1 blocks PKAonly
very weakly — enough to signiﬁcantly affect Gli1 mRNA levels, but not
enough to be discernible by semi-quantitative blotting for phospho-
PKA substrates. The ability of SDF-1 to enhance the effects of Shh-N in
cGCP is further evidence that theG-protein/AC/PKApathway plays a crit-
ical role in modulating the response of cGCPs to the Shh signal.
3.5. Shh target gene expression is not inversely correlated with total PKA
activity
The currently predominant paradigm of Shh signaling assumes that
PKA activity must be abrogated in order for the Shh pathway to be acti-
vated [30,35,36]. Our results showing an increase in Gli1 expression in
cells treated with a PKA inhibitor (Fig. 2A) seem to corroborate this
model.We therefore expected Shh-N to be able to have a negative effect
on the phosphorylation of PKA substrates in cGCPs. Surprisingly, wefound no evidence of Shh-N affecting PKA activity (Fig. 4A). Also, PKA
activity in untreated cells is barely detectable, as opposed to that in
cells treated with PACAP (Figs. 2A, 4B). This raised the question of
how target gene expression is kept silent in the absence of Shh. We hy-
pothesized that only a small pool of PKA is under the direct control of
Shh and that this pool is sufﬁcient to keep the pathway in the off state
in untreated cells. If that were the case, we would expect that under
some circumstances high levels of Shh signal might coexist in the
same cell with activated PKA, as long as PKA activation was limited to
a Shh-independent pool of PKA. In order to test this assumption, we
co-treated cGCPswith Shh-N and a low dose (1 nM) of PACAP. Striking-
ly, in these cells both Gli1 and total cellular PKA activity are signiﬁcantly
higher than in control cells (Fig. 4B), providing strong evidence for the
partial independence of Shh signaling from the pool of PKA activated
by PACAP. In summary, the relationship between total cellular PKA ac-
tivity and Shh signaling is not a simple inverse correlation. Instead, a
new model involving compartmentalization of PKA activity seems to
be most consistent with our data.
One concern with these data was that the observed discrepancy be-
tween activation of global PKA activity and inhibition of Shh signaling
could be due to cell-to-cell differences in our primary cultures. For ex-
ample, one could imagine that the cells that expressed Gli1 were not
the same as cells in which PACAP induced PKA activity. In order to ad-
dress this issue, we established a stable NIH/3T3 ﬁbroblast ﬂp-in cell
line expressing low levels of the mouse PAC1 receptor from a single
Fig. 3. PKA inhibition induces Hh target gene expression. (A) cGCPs were treated for 6 h with indicated doses of H89. Gli1 RT-PCRwas performed on isolated RNA. ***— p b 0.001 relative
to control, n/d — no data. (B) Anti-phospho-PKA-substrate western blot of samples treated with H89 (doses as in (A) above) or vehicle (DMSO) for 2 h. (C) cGCPS were pretreated for
30 min with 30 μM H89, then treated for 6 h with 1 μg/mL Shh-N, 10 nM PACAP, or both in the presence of H89. (D) cGCPs were treated for 6 h with PKA inhibitors PKI (10 μM) and
Rp-cAMPS (250 μM). Experiment was performed as in (A) * — p b 0.05, *** — p b 0.001 relative to control. (E) SDF-1 synergizes with Shh. cGCPs were cultured for 6 h in deﬁned
media in the presence of 25 mM KCl with the addition SDF-1 (1 μg/mL) and/or Shh-N at indicated doses. Gli1 expression was analyzed by RT-PCR.
Fig. 4.Gli1 expression is partially independent of global PKA activity. cGCPs were cultured
in deﬁned media in the presence of indicated concentrations of PACAP and Shh-N for 6 h
(for RT-PCR) or 2 h (for western blot). (A) Anti-phospho-PKA substrate western blot was
performed on protein isolated from cGCP samples. (B) RT-PCRwas performed on RNA iso-
lated from cGCPs (top panel) and anti-phospho-PKAwestern blot was performed on pro-
tein from corresponding samples (bottom panel).
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nist SAG induced Gli1 protein expression, and PACAP antagonized this
effect in a dose-dependent manner (Fig. 5A). Similarly to what we ob-
served with Shh pathway activation in cGCPs, SAG failed to decrease
global levels of PKA-mediated phosphorylation (Fig. 5B). Moreover, in-
crease of PKA target protein phosphorylation induced by 1–10 nM
PACAP could not fully counteract the effect of SAG on Gli1 production,
while a high dose of PACAP (100 nM) completely abrogated Gli1
upregulation by SAG (Fig. 5A). This is consistentwithwhatwe observed
in cGCPs, suggesting that our earlier observations (Fig. 4B) are not
explained by heterogeneity in primary cGCP cultures.
3.6. Gli2 trafﬁcking is partially insensitive to global PKA activity
To further explore the molecular mechanisms of the interaction be-
tween PACAP and Shh, we investigated how PACAP affected the trafﬁck-
ing of Gli proteins. Gli1 was not an appropriate protein to study in this
context, because it is mostly regulated at the level of transcription. In-
stead, we examined subcellular localization of Gli2, whose expression
does not change upon SAG treatment, andwhich instead is regulated di-
rectly by posttranslational modiﬁcations and intracellular trafﬁcking.
Upon Hh pathway activation, Gli2 accumulates at the tip of the primary
cilium, a small microtubule-based protrusion of the cell membrane
known to be essential for Hh signaling [37]. This ciliary trafﬁcking step
is hypothesized to be necessary for the subsequent nuclear translocation
of Gli2, and for Gli2-mediated transcriptional activation of target genes
[30,36]. Accordingly, SAG treatment induces a strong accumulation of
Gli2 at tips of primary cilia (Fig. 5C) and in the nuclei (Fig. 5B) of PAC1
FI cells. Importantly, neither SAG-mediated ciliary accumulation, nor
Fig. 5. Subcellular localization of Gli2 is partially independent of total cellular PKA activity in FI cells stably-transfected with PAC1. (A) PAC1 FI cells were treated for 24 h with SAG
(100 nM), with or without PACAP or IBMX (100 μM) + FSK (0.1 μM). Gli1 western blot was and Gli1 expression was quantiﬁed by western blot. (B) PAC1 FI cells were treated for 2 h
with SAG (100 nM) and PACAP (1–100 nM), as indicated. The cells were fractionated to separate nuclei from the cytoplasm and each fraction was blotted separately. Tubulin and
lamin are only present in the cytoplasm and nuclei, respectively. “C” — cytoplasmic fraction, “N” — nuclear fraction, gray and purple bars represent, respectively, the relative abundance
ofGli2 in the cytoplasmic and nuclear fractions. (C) PAC1 FI cellswere treated for 4 hwith SAG (100 nM) and PACAP (1–10 nM)were indicated. The cellswere ﬁxed and stainedwith anti-
Gli2 and anti-acetylated-tubulin antibodies, and imaged on a confocal microscope. Gli2 ﬂuorescence at the cilium tip was quantiﬁed for n = 64–70 cells from at least 3 separate ﬁelds of
view. Each gray circle represents a single cilium and bars represent median ± 95% conﬁdence interval on a log scale of ﬂuorescence intensity. Images below the chart show a represen-
tative cilium for each treatment group; **— p b 0.01, *** p b 0.001, n/s— not signiﬁcant. (D) The “two brake”model of the interplay between the Shh pathway and PKA-mediated signal-
ing. Left panel: in the absence of Shh, PKAShh is activated by Gpr161 and prevents Gli protein translocation into the primary cilium, ultimately resulting in their conversion into
transcriptional repressors (GliR). Middle panel: in Shh-treated cells, Smo enters the cilium, which causes Gpr161 to exit the cilium and abrogates PKAShh activity. Gli proteins accumulate
in tips of cilia and are converted into transcriptional activators (GliA). Right panel: in cells treated with Shh and PACAP, PKAShh remains off, and instead a second pool of PKA, PKAGPCR
becomes activated by the PACAP receptor PAC1. If PKAGPCR activity is sufﬁciently high, it will block Gli ciliary translocation and stimulate GliR formation. See the Discussion section for
a detailed explanation.
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with 1 nM PACAP, a dose that signiﬁcantly increases phosphorylation
of PKA substrates (Fig. 5B, C). In contrast, higher doses of PACAP (10–
100 nM) completely abolish SAG-induced changes in Gli2 localization.
These results are consistent with the effects of PACAP on Gli1 production
in both cGCP and PAC1 FI cells, and demonstrate that the paradigmof the
antagonism between cellular PKA and Shh signaling needs to be reﬁned.
4. Discussion
Protein kinase A is a major inhibitor of Shh signaling. It is now well
established that loss of PKA signaling is sufﬁcient to activate transcrip-
tion from Shh-sensitive promoters almost to the same extent as the
binding of Shh to Ptch [5,6,34] (Fig. 3B). This data suggests that PKA be-
longs to the core Shh signaling, lying at a step downstream of Smo and
upstream of Gli transcription factors. In the simplest model Smo would
repress PKA activity, which in turn would repress Gli proteins. A simplesequential repression model, however, requires that the baseline PKA
activity be high, so that Gli proteins can be kept inactive in the absence
of treatment. This is not consistent with our observations, since the two
Shh-responsive cell types that we tested had barely detectable baseline
PKA phosphorylation (Figs. 2A, 5B). This is not surprising, since
maintaining high PKA activity constantly in all Shh-responsive cells
would be energetically costly and would likely result in non-speciﬁc
phosphorylation of substrates belonging to other signaling pathways.
Another ﬂaw of the sequential repression model is that cells could not
maintain robust responses to Shh given their highly variable comple-
ment of GPCRs, each of which could in principle affect global PKA levels.
Our study shows for the ﬁrst time that high Shh signal can be
maintained despite large variations in total cellular PKA activity
(Fig. 4B). We also demonstrate that high overall levels of PKA-
mediated phosphorylation are not required to keep Shh signaling silent.
The most parsimonious way to explain this paradoxical uncoupling of
Shh signaling from PKA activity is to suggest that two pools of PKA
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Shh signaling and is turned on in untreated cells. This pool is sufﬁcient
to shut down signaling in the absence of Shh ligand,most likely because
it co-localizes well with Gli proteins, which are its primary effectors.
Since Gli proteins characteristically undergo trafﬁcking to primary
cilia, it is tempting to speculate that PKAShh is localized in the periciliary
region. Consistent with that claim, PKA accumulation at the base of pri-
mary cilia has been shown previously through the use of FRET-based
sensors and has been stipulated to play a role in Shh signaling in
cGCPs and in the developing spinal cord [6,35]. PKA is maintained at
the base of cilia by interacting with protein scaffolds known as AKAPs
anchored at the basal body, and inhibition of this interaction by the
cell-permeable peptide St-Ht31 abolishes Shh-mediated proliferation
in cGCPs [35]. Phosphodiesterases (PDE), which accompany PKA on
AKAP scaffolds and serve to limit the area of high cAMP concentration,
also appear to play a role in Shh signaling. Treatment of NIH/3T3
cells with the cAMP PDE inhibitor IBMX signiﬁcantly reduced SAG-
mediated Gli1 production (Fig. S3).
How might cells maintain the high localized PKA activity at the cili-
um base? It has recently been discovered that a ciliary Gs-coupled re-
ceptor Gpr161 is crucial for Shh signaling inhibition at baseline [13].
This receptor, acting through the AC/PKA cascade could well be respon-
sible for maintaining high baseline activity of PKAShh. Its exit from the
ciliumupon stimulation of Smomight constitute a plausiblemechanism
for Shh-mediated abrogation of PKAShh activity.
The second of the two putative PKA pools, which we will refer to as
PKAGPCR, is mostly inactive in the absence of cognate ligands. It is not
concentrated at the cilium and responds to stimulation by GPCRs dis-
tributed throughout the plasma membrane, such as the PACAP and
SDF-1 receptors. Its moderate activation by GPCR ligands does not
fully abrogate Shh signaling, but high levels of PKAGPCR activity are still
sufﬁcient to phosphorylate, and thus inhibit, most Gli proteins.
What results from the interplay of the two PKA pools is a model not
unlike a “two brake” system in an automobile. PKAShh constitutes the
“parking brake”, which must be released in order for Shh signaling to
commence. PKAGPCR is the “foot brake pedal”, which can adjust the
levels of signaling or even completely stop the pathway if pressed sufﬁ-
ciently hard.
What makes the “two brake”model operate is the localization of Gli
proteins to primary cilia, where they interact with PKAShh. Interestingly,
we show that ciliary accumulation of Gli proteins is itself regulated by
both Shh signaling and by PACAP (Fig. 5C).We believe that the inhibition
of ciliary transport of Glis by PACAP is mediated through the AC/PKA
pathway. Stimulation of AC by FSK has been previously shown to abro-
gate Gli ciliary accumulation, but this effect was assumed to be non-
speciﬁc, since it persisted in cells lacking all major α and β catalytic sub-
units of PKA [6]. In contrast, we show that a similar effect can be achieved
through physiological induction of the AC/PKA pathway by PACAP. Two
possible explanations of the discrepancy can be advanced. The effect of
PACAP and FSK on Gli localization could be mediated through AC but in-
dependently of PKA, and therefore would be preserved in PKA mutant
mice. Alternatively, the inhibitory effect of FSK in PKA mutant cells
could have been mediated by the γ catalytic subunit of PKA [38],
which, although not normally strongly expressed in the neural tube,
could have become ampliﬁed in mutant mice as a compensatory mech-
anism. We favor the latter explanation, because transient inhibition of
PKA by PKI, which cannot induce compensation, is sufﬁcient to stimulate
Gli accumulation at cilia (P.N., unpublished data). In conclusion, we be-
lieve that PACAP regulates Shh signaling through the AC/PKA cascade
by affecting the intracellular trafﬁcking of Gli proteins to the primary
cilium.
Interestingly, Hh signal transduction seems to have diverged signif-
icantly betweenmammals andDrosophila. Not only are cilia dispensable
for Hh signaling in theﬂy, but also Smo appears to act in this species as a
bona ﬁde Gi-coupled receptor, regulating intracellular cAMP and thus
able to affect global PKA activity [8]. Direct Gi coupling also seems tobe essential for non-canonical Gli-independent induction of Rho small
GTPases by Smo. Importantly, Rho induction by Smo is preserved in a
ciliary-localization deﬁcient variant of Smo, stressing the independence
of Gi-linkage of Smo of its ciliary localization [12]. Therefore, the “two
brake” system appears to be a characteristic feature of only the canoni-
cal, cilium-dependent vertebrate Hh signaling, perhaps reﬂecting its
adaptation to a diverse set of functions played by this pathway in verte-
brate development.
One example of the utility of the “two brake” system is the role it
plays in blocking Shh-pathway-dependent tumorigenesis during cere-
bellar development. Deletion of one copy of Ptch effectively damages
the “parking brake” PKAShh pool in the neonatal cerebellum, leading to
MB formation in mutant mice [39]. In these mice PKAGPCR is the only
pool that can stop excessive proliferation. Additional mutation of
PACAP makes this “brake pedal” PKA pool less effective, thus leading
to increased incidence and aggressiveness of the tumors [27]. Impor-
tantly, PKAGPCR should remain intact in most Shh-driven malignancies,
which makes it possible to inhibit Shh-dependent tumorigenesis by
treatment with an appropriate GPCR ligand, such as PACAP [27,40]. An
evenmore attractive therapeutic approach would be to prevent the ab-
errant Shh signal from releasing the “parking brake”. Some important
insights into the regulation of this PKApool have recently been provided
[6,9,13,35], but a therapeutically exploitable strategy to target PKAShh
remains to bedevised. Our study should be a valuable stepping stone to-
ward that goal.
5. Conclusions
• PACAP blocks Shh signaling through PKA inhibition.
• Shh affects Gli protein localization and target gene transcription by
regulating a compartmentalized pool of PKA.
• The interplay between PACAP- and Shh-controlled PKA pools results
in ﬁne-tuning of the Shh-induced transcriptional program and plays
a role in cerebellar development and disease.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2013.07.012.
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